文献速递糖尿病垂体与肾上腺疾病

儿童期矮身材接受生长激素治疗后成年早期糖尿病治疗风险

Risk of Diabetes Treated in Early Adulthood After Growth Hormone Treatment of Short Stature in Childhood.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

法国一项基于人群的队列纳入5100例儿童期因特发性孤立性生长激素缺乏、特发性矮身材或小于胎龄儿矮身材而于1985至1996年开始生长激素治疗的患儿,依据2009至2010年糖尿病药物发放数据评估糖尿病患病率。平均30岁时,生长激素治疗者与法国一般人群的治疗糖尿病(口服药或胰岛素)患病率无差异,胰岛素治疗的妊娠糖尿病风险亦相似。作者认为结果令人安心,但需更长时间随访以评估随年龄增长的糖尿病风险。

要点

  • 平均30岁时,生长激素治疗者与法国一般人群的治疗糖尿病患病率无差异,男女均如此。
  • 胰岛素治疗的妊娠糖尿病风险在患者与参考人群间相似。
  • 作者认为结果令人安心,但需更长时间随访评估随年龄增长的糖尿病风险。

核心结论

  • 生长激素治疗患者与参考人群的糖尿病风险无差异,结果令人安心,但需更长时间随访以评估这些患者随年龄增长的糖尿病风险。

研究设计与样本

  • 基于人群的队列研究,纳入5100例儿童期因特发性孤立性生长激素缺乏、特发性矮身材或小于胎龄儿矮身材而于1985至1996年开始生长激素治疗的患儿。
  • 糖尿病药物发放数据来自法国国家健康保险数据库2009年和2010年记录,患者与对照的病例均依据糖尿病药物发放识别。

主要发现

  • 平均年龄30岁时,生长激素治疗者与法国一般人群的治疗糖尿病(口服药或胰岛素)患病率无差异,无论性别。
  • 胰岛素治疗的妊娠糖尿病风险在患者与参考人群间相似。

局限性

  • 原文指出需更长时间随访的研究以评估这些患者随年龄增长的糖尿病风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Growth hormone (GH) is known to be diabetogenic, but the risk of diabetes in individuals treated with GH in childhood has been little evaluated, and conflicting results have been obtained. OBJECTIVE: To investigate the prevalence of diabetes and gestational diabetes in a population-based cohort of patients treated with GH for short stature in childhood in France. DESIGN, SETTING, AND PARTICIPANTS: Participants were a population-based cohort of 5100 children with idiopathic isolated GH deficiency, idiopathic short stature, or short stature in children born short for gestational age who started GH treatment between 1985 and 1996. Data on the delivery of diabetes drugs in 2009 and 2010 were obtained from the French national health insurance database. Cases in patients and controls were identified from diabetes drugs deliveries. MAIN OUTCOME MEASURE: The prevalence of diabetes was calculated and compared with that in the general population, determined on the basis of data from the same source, with the same definition. RESULTS: At a mean age of 30 years, no difference in the prevalence of treated diabetes (oral drugs or insulin) was found between subjects treated with GH and the general population in France, regardless of sex. Similarly, the risk of insulin-treated gestational diabetes was similar in patients and in the reference population. CONCLUSIONS: No difference in the risk of diabetes was found between GH-treated patients and the reference population. These results are reassuring, but further studies with a longer follow-up are required to evaluate the risk of diabetes with age in these patients.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Poidvin A, Weill A, Ecosse E, et al. Risk of Diabetes Treated in Early Adulthood After Growth Hormone Treatment of Short Stature in Childhood. J Clin Endocrinol Metab. 2017. PMID: 28324032. doi:10.1210/jc.2016-3145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。